Developing new therapies for metastatic cancers including hematological disease

NucliThera a.s is an R&D company developing targeted short range radionuclides for treating metastatic cancers including lymphoma and leukemia. High-energy alpha- and beta-radiating nuclides are linked to targeting monoclonal antibodies or small molecules. They bind to cancer cells killing them with minimal damage to surrounding healthy tissue.

The NucliThera research team is led by Dr. Roy H Larsen and Professor Emeritus Øyvind S Bruland. They have developed the only alpha-emitting cancer pharmaceutical approved by FDA so far – Xofigo against bone metastases from prostate cancer. Xofigo was acquired by Bayer Healthcare for US$ 2.9 billion in 2014.

Information about employment and more at Linkedin.